


How long could the patients survive after initiation of HIV treatment ?



HIV: Infinity War or End Game? Updates on HIV Cure and Remission

Opass Putcharoen MD, MSc

Division of Infectious Diseases, Department of Medicine,
Faculty of Medicine, Chulalongkorn University
Emerging Infectious Diseases Clinical Center, Thai Red Cross
Bangkok, Thailand



OUR FIGHT ISN'T OVER.

PEOPLE LIVING WITH HIV STILL FACE STIGMA IN
SCHOOL, WORK, PUBLIC, AND EVEN IN HEALTHCARE.

HIV STIGMA: #LETSENDIT





I'll begin with the end My summary

- HIV eradication is difficult but may be possible
 - Attack at HIV reservoir
 - Enhance human immune response
 - Make human cells resistant to HIV infection




Effects of current ART on plasma viral load and HIV reservoirs




HIV'S MANY RESERVOIRS


Beyond lying in wait in dormant memory T cells, HIV may reproduce at a low rate in certain other immune system cells—particularly macrophages and dendritic cells that seem inherently able to ward off immune defenses and anti-HIV drugs to some extent. Further, HIV-infected cells in a few parts of the body may be physically shielded to a degree from the immune system and certain drugs. HIV made in cellular and anatomical reservoirs does not reach the blood readily in aggressively treated patients but might generate a vigorous infection if treatment stops.




Advances in ART



At the anatomical level



At the cellular level





Kulpa and Chomont *Journal of Virus Eradication* 1: 59-66 (2015)

Basics

Why HIV eradication is very difficult?

Concepts of HIV Cure

Some people have self immunity to protect from HIV infection




Why HIV eradication is very difficult?

Basics

Concepts of HIV Cure

Some people have self immunity to protect from HIV infection



Fate of latently infected T cells


- Activated by antigen or drugs
→ destroyed by CTL or CPE
- Resting and clonal expansion



Type and principle of HIV Cure


Functional Cure

When the level of HIV particles in an infected person's body has been reduced to such an **extremely low level** that person can stop treatment and not worry about viral rebound and damaging immune system



Sterilizing cure

When every last particle of HIV has been destroyed from an infected person's body (eradication)



Somethings that you need to know

Some people got HIV but then viruses disappeared by interventions

Some people got HIV but then viruses were maintained at low level without drug



Some people have self immunity to protect from HIV infection

Somethings that you need to know

Some people got HIV but then viruses disappeared by interventions


Some people got HIV but then viruses were contained at very low level "without" drug

Some people have self immunity to protect from HIV infection





N Engl J Med 2009; 360:692-698

Natural resistance to HIV infection



ต้นแบบของการรักษาโรคติดเชื้อเอชไอวีให้หายขาด



Frequencies of gene variant CCR5-Δ32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers Human Immunology 78 (2017) 710-717




Basics

Why HIV eradication is very difficult?

Concepts of HIV Cure

Some people have self immunity to protect from HIV infection




	London patient	Berlin patient
เสถียรเซลล์ของ HIV	ปลูกถ่ายเสถียรเซลล์จากคนที่เป็น CCR5Δ32 homozygous	ปลูกถ่ายเสถียรเซลล์จากคนที่เป็น CCR5Δ32 homozygous
ลักษณะของเซลล์ของ HIV	มี CCR5 ประกติ	มี CCR5 แบบ heterozygous
สายพันธุ์ของเชื้อเอชไอวี	ติดเชื้อไวรัสสายพันธุ์ R5	ติดเชื้อไวรัสสายพันธุ์ R5
โรคมะเร็งที่ผู้ป่วยเป็น	Hodgkin lymphoma	Acute myelogenous leukemia
จำนวนครั้งของการปลูกถ่าย	ทำการปลูกถ่ายเสถียรเซลล์ครั้งเดียว	ทำการปลูกถ่ายเสถียรเซลล์สองครั้ง
การฉายรังสีเพื่อกำจัดเซลล์มะเร็ง	ไม่ได้รับการฉายแสงเพื่อกำจัดเซลล์มะเร็ง	ได้รับการฉายแสงเพื่อกำจัดเซลล์มะเร็ง
สูตรยา conditioning regimen	Reduced intensity	Full intensity
ยากกดภูมิคุ้มกัน T cell	ได้รับ antiCD52	ได้รับ ATG
การเกิดภาวะ Graft versus host disease	เล็กน้อย	เล็กน้อย
Chimerism	100% chimerism	100% chimerism
ระยะเวลาหลังจากหยุดยาดำเนินการตรวจหาไวรัสอีกเลย	1 ปีครึ่ง REMISSION	12 ปี CURE
ไวรัสในแหล่งต่างๆ	ยังตรวจไม่พบ	ตรวจไม่พบไวรัสทุกชนิดในอวัยวะต่างๆ เช่น สมอง ลำไส้ ต่อม้ำตาเหลือง

CCR5 เป็นโปรตีนบนผิวเซลล์ที่เชื้อเอชไอวีใช้เป็นตัวพาเข้าไปในเซลล์ของ CCR5Δ32 homozygous = คนที่ไม่มีโปรตีนนี้เลยบนเซลล์ ทำให้เชื้อไม่สามารถเข้าไปได้
Conditioning regimen = การให้ยาหรือวิธีการต่างๆ ที่ทำให้เซลล์ในไขกระดูกถูกทำลายลงเพื่อให้เซลล์ใหม่เข้าไปแทนที่
Graft versus host disease = กลไกที่ร่างกายของผู้รับเซลล์มีการต้านเซลล์ที่รับเข้ามา ซึ่งมีข้อดีคือเซลล์ที่มีไวรัสซ่อนอยู่ในผู้รับอาจถูกกำจัดได้ด้วยวิธีนี้
Chimerism = การที่เซลล์ของผู้รับและผู้ให้เข้ากันได้ หลังจากการปลูกถ่ายเสถียรเซลล์

Type and principle of HIV Cure

Functional Cure


When the level of HIV particles in an infected person's body has been reduced to such an **extremely low level** that person can stop treatment and not worry about viral rebound and damaging immune system



Sterilizing cure

When every last particle of HIV has been destroyed from an infected person's body (eradication)

Sterilizing Cure in Berlin and London patient



How many have been on ART?

23 million (WHO 2018)


How many have been cured?

At least (2+1)+14

2018

37.9 million people


How to replicate this kind of treatment and make more applicable for a large-scale treatment




Long-term control of viremia and stable CD4 T cells in 14 cases after stop ART!!

Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study





PLOS PATHOGENS



Functional cure




We need T cells for HIV control






Immune control in HIV infection

- CD4 T cells coordinate in immune function against infection
- HIV infect CD4+ cells (most CD4+ T cells)
- Infected CD4 T cells may die or survive




PLoS Pathog 13(12): e1006753.

- ### Engineering T cells with
- Enhanced activity to target HIV
 - Resistant to HIV infection



Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS

PLoS Pathog 13(12): e1006753.









Making cell resistant to HIV

Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV


THE NEW ENGLAND JOURNAL of MEDICINE



N Engl J Med 2014;370:901-10

Making cell resistant to HIV

Engineering HIV-Resistant Human CD4+ T Cells with CXCR4 or CCR5 -Specific Zinc-Finger Nucleases



ACTGGAACACAACACCCACAAGTCATTGGGCTAGAAGCGGTCACAGATATATC
 ACTGGAACACAACCAACCCACAAGTCATT GGTAGAAGCGGTCACAGATATATC
 ACTGGAACACAACCAACCCACAA GTAGAAGCGGTCACAGATATATC
 ACTGGAACACAACCAACCCACAA GAAGCGGTCACAGATATATC
 ACTGGAACACAACCAACCCACAA GCGGTCACAGATATATC
 ACTGGAACACAACCAACCCACAA GTCACAGATATATC
 ACTGGAACACAACCAACCCACAA GATATATC
 ACTGGAACACAACCAACCCACAAGTCATTGGTGGGGTAGAAGCGGTCACAGATATATC


Reference
 2bp deletion (1.4%)
 9bp deletion (4.5%)
 12bp deletion (2.6%)
 15bp deletion (5.2%)
 18bp deletion (11.2%)
 25bp deletion (1.6%)
 4bp insertion (2.5%)

PLOS PATHOGENS


TAKE THE NEXT STEP...






Making cell resistant to HIV



How CRISPR used in HIV Cure?




Making cell resistant to HIV




Outcomes



- 😊 Gene disruption
- 😊 Gene editing
- 😊 Gene addition
- 😞 Off target



Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice



Mice with human T cells, that are broadly susceptible to HIV-1 infection



Development of CRISPR for HIV treatment



Chinese Scientist Claims to Use Crispr to Make First Genetically Edited Babies

The researcher, He Jiankui, offered no evidence or data to back up his assertions. If true, some fear the feat could open the door to "designer babies."

CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia

THE NEW ENGLAND JOURNAL OF MEDICINE

Homogenization




Nanoparticles

Size

Shape

Charge



Cellular Testing

Drug	Formulation	Cell Uptake		Cell Retention		Cell Release		Antiretroviral		Toxicity		Final Score	
		AUC	Score	AUC	Score	AUC	Score	AUC	Score	Y/N	Score	Total	Score
DTG	H433	185	10.0	500	10.0	23	7.5	15000	10.0	N	10.0	47.5	9.5
	H333	150	8.6	350	8.4	16	5.0	20000	9.2	N	10.0	41.2	8.2
	M412	70	4.5	88	2.0	29	8.1	43000	3.6	Y	5.0	23.2	4.6
	H134	36	2.5	30	1.0	35	10.0	66500	2.5	N	10.0	26.0	5.2

Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing

Rafal Kaminski^{1,2}, Yilan Chen^{1,2}, Tracy Fischer^{1,2}, Ellen Tedaldi^{1,2}, Alessandro Napoli^{1,2}, Yonggang Zhang^{1,2}, Jonathan Karn¹, Wenhui Hu^{1,2} & Kamel Khalili^{1,2}



ARTICLE

<https://doi.org/10.1038/s41467-019-10364-y> OPEN

Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice



SCIENTIFIC REPORTS | 6:22555 | DOI: 10.1038/srep22555

Gene-Edited Babies: What a Chinese Scientist Told an American Mentor

Chinese Scientist Claims to Use Crispr to Make First Genetically Edited Babies


The researcher, He Jiankui, offered no evidence or data to back up his assertions. If true, some fear the feat could open the door to "designer babies."

World's First Gene-Edited Babies Born This Month, Researcher Says




CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia

N Engl J Med 2019;381:1240-7.



The percentage of CD4+ cells with CCR5 ablation increased by a small degree during a period of antiretroviral-therapy interruption



- Current HIV cure cases: we are counting
- Role of precision medicine in HIV treatment
 - CART T cell therapy
 - Gene editing for HIV control and eradication



CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia

N Engl J Med 2019;381:1240-7.

